MHC-I INTRATUMOR HETEROGENEITY DETERMINES ONCOGENIC AND METASTATIC CAPACITY, AND IMMUNE RESPONSE

被引：0
|
作者：
Romero-Garcia, Irene [1 ]
Linares, Isabel [1 ]
Algarra, Ignacio [2 ]
Collado, Antonia [3 ]
Garrido, Federico [1 ]
Garcia-Lora, Angel [1 ]
机构：
[1] Hosp Univ Virgen de las Nieves, UGC Lab Clin, Granada, Spain
[2] Univ Jaen, Dept Ciencias Salud, Jaen, Spain
[3] Hosp Univ Virgen de las Nieves, Unidad Invest, Granada, Spain
来源：
TISSUE ANTIGENS | 2014年 / 84卷 / 01期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [31] In vitro genetic reprogramming increases MHC-I expression and ameliorates resistance to an antitumor immune response in Merkel cell carcinoma
    Luly, K. M.
    Green, J. J.
    Tzeng, S. Y.
    Sunshine, J. C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S1 - S1
  • [32] Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation
    Estephan, Hala
    Tailor, Arun
    Parker, Robert
    Kreamer, Mckenzie
    Papandreou, Ioanna
    Campo, Leticia
    Easton, Alistair
    Moon, Eui Jung
    Denko, Nicholas C.
    Ternette, Nicola
    Hammond, Ester M.
    Giaccia, Amato J.
    EMBO JOURNAL, 2025, 44 (03): : 903 - 922
  • [33] Loss of MHC-I expression is associated with altered immune microenvironment and decreased response to PD-1 checkpoint inhibition
    Gstalder, Cecile
    Pancholi, Priya
    Sadowicz, Dorota
    Haq, Rizwan
    CANCER RESEARCH, 2018, 78 (13)
  • [34] A Cell-Surface MHC-I Inhibitory Axis Promotes Immune Evasion in Cancer
    不详
    CANCER DISCOVERY, 2023, 13 (10) : 2120 - 2120
  • [35] Early lung adenocarcinoma subtyping based on MHC-I and II immunogenic response
    Senosain, Maria-Fernanda
    Zou, Yong
    Patel, Khushbu
    Irish, Jonathan M.
    Pancaldi, Vera
    Massion, Pierre P.
    CANCER RESEARCH, 2021, 81 (05)
  • [36] Mechanisms of MCMV immune evasion provide insight into MHC-I folding and assembly.
    May, Nathan A.
    Boyd, Lisa
    Margulies, David H.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [37] A membrane-associated inhibitory axis of MHC-I presentation for cancer immune evasion
    Lu, Qiao
    Chen, Xufeng
    Zhou, Hua
    Liu, Jia
    Nadorp, Bettina
    Lasry, Audrey
    Sun, Zhengxi
    Zhang, Jiangyan
    Cammer, Michael
    Wang, Kun
    Ciantra, Zoe
    You, Jia
    Guo, Qianjin
    Zhang, Hongbing
    Sengupta, Debrup
    Boukhris, Ahmad
    Liu, Cheng
    Cresswell, Peter
    Dahia, Patricia L. M.
    Aifantis, Iannis
    Wang, Jun
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [38] Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration
    Morinaga, Takao
    Inozume, Takashi
    Kawazu, Masahito
    Ueda, Youki
    Sax, Nicolas
    Yamashita, Kazuo
    Kawashima, Shusuke
    Nagasaki, Joji
    Ueno, Toshihide
    Lin, Jason
    Ohara, Yuuki
    Kuwata, Takeshi
    Yukami, Hiroki
    Kawazoe, Akihito
    Shitara, Kohei
    Honobe-Tabuchi, Akiko
    Ohnuma, Takehiro
    Kawamura, Tatsuyoshi
    Umeda, Yoshiyasu
    Kawahara, Yu
    Nakamura, Yasuhiro
    Kiniwa, Yukiko
    Morita, Ayako
    Ichihara, Eiki
    Kiura, Katsuyuki
    Enokida, Tomohiro
    Tahara, Makoto
    Hasegawa, Yoshinori
    Mano, Hiroyuki
    Suzuki, Yutaka
    Nishikawa, Hiroyoshi
    Togashi, Yosuke
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (07): : 739 - 753
  • [39] Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway
    Xiaobo Luo
    Yan Qiu
    Zackary R. Fitzsimonds
    Qiuhao Wang
    Qianming Chen
    Yu Leo Lei
    Oncogene, 2024, 43 : 388 - 394
  • [40] Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation
    Zhang, Biying
    Li, Jiao
    Hua, Qingling
    Wang, Haihong
    Xu, Guojie
    Chen, Jiayuan
    Zhu, Ying
    Li, Ruiqi
    Liang, Qing
    Wang, Lanqing
    Jin, Min
    Tang, Jing
    Lin, Zhenyu
    Zhao, Lei
    Zhang, Dejun
    Yu, Dandan
    Ren, Jinghua
    Zhang, Tao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
12345